Marina Biotech this week said that the US Patent and Trademark Office has issued a notice of allowance for three of the company's patent applications related to its delivery technologies.

The European Patent Office has also said it will grant the company a patent on a related technology, Marina said.

According to the company, the USPTO patent applications relate to the Smarticle amphoteric-based liposomal delivery vehicles Marina acquired from Novosom in 2010. The EPO application covers its DiLA2 amino acid-based liposomal delivery system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.